1 / 4

Prostate Cancer Treatment: What’s Best for You

Prostate Cancer Treatment: What’s Best for You. Daniel P. Petrylak Professor of Medicine Columbia University Medical Center/NY Presbyterian Hospital. When does a patient see a medical oncologist. Local disease: As “unbiased” opinion for local therapy

koen
Download Presentation

Prostate Cancer Treatment: What’s Best for You

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Prostate Cancer Treatment: What’s Best for You Daniel P. Petrylak Professor of Medicine Columbia University Medical Center/NY Presbyterian Hospital

  2. When does a patient see a medical oncologist • Local disease: As “unbiased” opinion for local therapy • High Risk Disease: Add hormone or chemotherapy to decrease risk of relapse • Metastatic disease: Initiation of second line hormones, chemotherapy, radiation therapy

  3. High-Risk CAP: The Options • Surgery – Standard RP, wide/extended resection RP – Hormone therapy: NHT, AHT – ART – Chemotherapy: Neoadjuvant, adjuvant • RT – EBRT with NHT and/or AHT – Dose escalation – EBRT with chemohormonal therapy – Other RT techniques • HT alone • New therapies NHT = neoadjuvant hormone therapy; AHT = adjuvant hormone therapy; ART = adjuvant radiotherapy. Payne, 2009.

  4. Challenges for the Implementation of Multimodality Therapy • High risk local therapy • Role of chemotherapy not defined • Investigational studies require long follow-up due to the natural history of disease • By selecting the highest risk patients, reduce the available patient pool • Clinical trial accrual has been poor.

More Related